Mycosynthetix: Accelerating Drug Discovery Since 2001

About

Mycosynthetix Management and Board Members

Cedric Pearce, Ph.D.
Dr. Cedric Pearce is founder and CEO of Mycosynthetix. For the past thirty years Dr. Pearce has worked with medicines and agrochemicals from microbes and has extensive experience in natural products and their applications. He was awarded a PhD from the University of Southampton in the UK and was a Royal Society European Exchange Fellow at the Institut de Chimie des Substances Naturelle in France before moving to the University of Illinois in Champaign Urbana; during this entire period he conducted research on antibiotics and related microbial products. He continued to work on medicines from fungi and other microorganisms as a faculty member at University of Connecticuts School of Pharmacy and in the commercial sector. For seven years he was engaged in research on microbial products in the pharmaceutical industry, working with the antitumor group at Bristol Myers, and then in the Infectious Disease Research Section of American Cyanamid`s Medical Research Division. Subsequent engagements were within the biotechnology sector, including periods with MYCOsearch and then OSI Pharmaceuticals where he held increasingly senior roles up to Director of the natural products drug discovery division. After a period with a life science venture capital firm (A.M.Pappas) he founded Mycosynthetix in August 2001. Dr Pearce has published and lectured extensively on medicines and other products from microorganisms, and is inventor on a number of issued patents. He is currently an Associate Editor for the Journal of Natural Products, and an adjunct professor in the Chemistry and Biochemistry Department and a Coleman Foundation Entrepreneurship Fellow at the University of North Carolina in Greensboro.
William McCulloch, M.B., Ch.B., F.R.C.P., F.F.P.M.

What is tadalafil? Read here!
Shop where you can buy duty free alcohol online.
Newport menthols cigarettes to buy!
Shop of duty free cigarettes. Worldwide shipping!

Dr. McCulloch (Bill), a Mycosynthetix Board Member, practiced medicine for seven years in the U.K., including post-graduate training in Internal Medicine, Hematology and Oncology, before joining the international pharmaceutical industry in 1984. Since then, his career as a senior R&D executive in a variety of large and small companies has afforded him extensive experience in developing and commercializing technologies. His areas of responsibility have included non-clinical and clinical development, regulatory and medical affairs, licensing and sales force training, with a focus in oncology and serious infectious diseases. He has undertaken all phases of drug and technology development, and has been directly involved in the U.S. and Europe in filing INDs/CTAs and NDAs/MAAs, securing Orphan Drug status for compounds and obtaining SBIR and other grant funding for his projects. Most recently he held the full time position of Chief Medical Officer then was Senior Medical Advisor for Gloucester Pharmaceuticals, Inc., where he led the regulatory strategy and oversaw the conduct of the pivotal trial which led to FDA approval of their HDAC inhibitor in November 2009 and the subsequent acquisition of the Company by Celgene Corporation in January, 2010. He is the President of Alba BioPharm Advisors, Inc., a consulting company he founded with his wife in 2002.

Nicholas Oberlies, Ph.D.
Nicholas H. Oberlies, Ph.D., a Mycosynthetix Board Member, is Associate Professor of Chemistry and Biochemistry at The University of North Carolina at Greensboro. He received his B.S. in Chemistry from Miami University (Oxford, Ohio) and his Ph.D. in Medicinal Chemistry and Pharmacognosy from Purdue University (West Lafayette, Indiana), where he studied under Professor Jerry L. McLaughlin. He was a postdoctoral chemist at American Cyanamid (Princeton, New Jersey), and in 1998 joined the Natural Products Laboratory at Research Triangle Institute (RTI) in North Carolina, where he collaborated with Dr. Mansukh C. Wani and the now late, Dr. Monroe E. Wall, co-discoverers of taxol and camptothecin. He rose progressively through the ranks of RTI and eventually directed the Natural Products Laboratory. In 2009, he joined the Department of Chemistry and Biochemistry at the University of North Carolina at Greensboro. He leads a mulidisciplinary effort to identify, isolate, and characterize new drug entities from natural sources, such as plants, fungi, and bacteria. His lab also examines herbal drugs, especially for the development of reference standards. For more information see about his work see his faculty page at uncg.edu. Dr. Oberlies received the 2005 Matt Suffness Young Investigator Award from the American Society of Pharmacognosy, their highest distinction for young scientists. Dr. Oberlies has published over 40 peer reviewed manuscripts of original research, 8 reviews of the literature, and 7 book chapters.
Ramon Garcia, Ph.D.
Dr. Ramon L. Garcia, a Mycosynthetix Board Member, is the founder of InterLink. Dr. Garcia was one of the founders and CEO of InterLink Biotechnologies LLC, a company established in 1991 and acquired by Abraxis Biosciences Inc. (Nasdaq ABII) in September of 2003. InterLink Biotechnologies developed a unique drug discovery platform of novel natural products derived from microorganisms. Products resulting from the company activities include new pharmaceutical drugs, antimicrobial peptides, enzymes as additives for human food and animal feed products and bio-control agents. Dr. Garcia has been a Research & Development Senior Manager and CEO for more than twenty five years. He has directed research in the field of biotechnology with applications in pharmaceuticals, food, agriculture and chemicals. Dr. Garcia was responsible for starting and directing two major corporate biotechnology laboratories. His proven accomplishments include the development of new products and technologies and the transfer and licensing of new technologies. Dr. Garcia has worked on numerous assignments involving technology assessments, strategic planning, and technology transfer for a number of international corporations and universities. Ramon L. Garcia has a M.S. and Ph.D. from Iowa State University.